Johnson & Johnson selects Onco360 for LAZCLUZE pharmacy partnership

LAZCLUZE, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has recently received FDA approval for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. The approval follows positive results from the Phase III MARIPOSA study, which demonstrated significant benefits over traditional treatment options. Johnson & Johnson has selected Onco360 as the pharmacy partner for distributing LAZCLUZE.

Manufactured by Janssen Biotech, a division of Johnson & Johnson, LAZCLUZE is designed to offer a chemotherapy-free treatment option for patients whose tumors exhibit EGFR exon 19 deletions or exon 21 L858R mutations. This approval is in conjunction with that of RYBREVANT (amivantamab-vmjw). The combination of these medications aims to provide a more effective and tolerable treatment regimen for affected patients.

Clinical trials have highlighted the efficacy of LAZCLUZE when used in combination with RYBREVANT. The Phase III MARIPOSA study revealed that this treatment combination significantly reduces the risk of disease progression or death by 30% compared to the current standard treatment, osimertinib. Specifically, patients treated with the combination therapy experienced a median progression-free survival (PFS) of 23.7 months, in contrast to 16.6 months for those on osimertinib. Moreover, the median duration of response among patients was extended by nine months, showcasing the potential of this new regimen to greatly enhance patient outcomes.

Benito Fernandez, the chief commercial officer of Onco360, expressed gratitude for the opportunity to collaborate with Johnson & Johnson in distributing LAZCLUZE. He emphasized that Onco360 is proud to include this targeted therapy in their portfolio, offering a first-line, chemotherapy-free option for treating patients with locally advanced or metastatic EGFR-mutation NSCLC.

Overall, the introduction of LAZCLUZE, along with RYBREVANT, represents a significant advancement in the treatment of NSCLC. The promising results from the MARIPOSA study suggest that patients with specific EGFR mutations may benefit from this new, targeted approach, which focuses on improving progression-free survival and overall response rates without the need for traditional chemotherapy.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!